- Home
- RSLS vs TOVX Comparison
RSLS vs TOVX Comparison
Compare RSLS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- TOVX
- Stock Information
- Founded
- RSLS 2002
- TOVX 2001
- Country
- RSLS United States
- TOVX United States
- Employees
- RSLS N/A
- TOVX N/A
- Industry
- RSLS Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- TOVX Health Care
- Exchange
- RSLS Nasdaq
- TOVX Nasdaq
- Market Cap
- RSLS 3.2M
- TOVX 3.6M
- IPO Year
- RSLS 2007
- TOVX 2006
- Fundamental
- Price
- RSLS $3.57
- TOVX $1.28
- Analyst Decision
- RSLS Hold
- TOVX Strong Buy
- Analyst Count
- RSLS 1
- TOVX 1
- Target Price
- RSLS N/A
- TOVX $6.00
- AVG Volume (30 Days)
- RSLS 43.6K
- TOVX 247.7K
- Earning Date
- RSLS 03-31-2025
- TOVX 03-24-2025
- Dividend Yield
- RSLS N/A
- TOVX N/A
- EPS Growth
- RSLS N/A
- TOVX N/A
- EPS
- RSLS N/A
- TOVX N/A
- Revenue
- RSLS $8,183,000.00
- TOVX N/A
- Revenue This Year
- RSLS $17.47
- TOVX N/A
- Revenue Next Year
- RSLS $20.00
- TOVX N/A
- P/E Ratio
- RSLS N/A
- TOVX N/A
- Revenue Growth
- RSLS N/A
- TOVX N/A
- 52 Week Low
- RSLS $3.23
- TOVX $1.14
- 52 Week High
- RSLS $29.00
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- RSLS 33.36
- TOVX 40.44
- Support Level
- RSLS $3.23
- TOVX $1.15
- Resistance Level
- RSLS $3.92
- TOVX $1.30
- Average True Range (ATR)
- RSLS 0.31
- TOVX 0.09
- MACD
- RSLS -0.08
- TOVX -0.04
- Stochastic Oscillator
- RSLS 19.21
- TOVX 7.14
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.